DYSF and neuromuscular disease caused by qualitative or quantitative defects of dysferlin: Hence, we hypothesised that these molecular aspects might be rapidly exacerbated by GC treatment in dysferlinopathy and may manifest as the functional decline of dysferlin-deficient muscles within a short treatment period.